# Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

> **NCT07014917** · PHASE2 · RECRUITING · sponsor: **Zulfa Omer** · enrollment: 62 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- CLL Variant

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Acalabrutinib
- **DRUG:** Venetoclax
- **DRUG:** Acalabrutinib

## Key facts

- **NCT ID:** NCT07014917
- **Lead sponsor:** Zulfa Omer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-05
- **Primary completion:** 2028-06-05
- **Final completion:** 2032-06-05
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014917, "Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07014917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*